Nanocurie to Megabecquerel

Receptor binding assays are the classic example. A biochemist adds 2–5 nCi of tritium-labelled drug to a plate of cells and measures how much binds to a receptor versus washing away. Metabolic tracing studies use similar amounts of carbon-14-labelled glucose or amino acids to follow biochemical pathways. At nanocurie levels the radioactivity is low enough that bench work requires minimal shielding — a few centimeters of acrylic for tritium beta particles — but high enough to produce a detectable signal after hours of counting.

One nanocurie equals 37 Bq — about the activity of 2.5 bananas worth of potassium-40, or roughly 0.5% of the natural K-40 activity in your own body. A smoke detector contains about 30,000 nCi (1 µCi) of americium. The nanocurie sits in the gap between environmental levels you cannot avoid (picocuries) and laboratory quantities that require formal licensing (microcuries). It is the unit of "detectable but not dangerous," which is exactly why it suits low-level lab work.

Tritium (hydrogen-3) is the perfect biological tracer because hydrogen appears in every organic molecule. You can replace a hydrogen atom with tritium without changing the molecule's chemistry — the drug, amino acid, or sugar behaves identically in the cell. Tritium emits only very low-energy beta particles (max 18.6 keV) that cannot penetrate skin or even a lab bench surface, making it the safest radioisotope to handle. The downside is low specific activity, so you need sensitive liquid scintillation counting to detect it — but at nanocurie levels, that is perfectly adequate.

In the US, NRC exempt quantities vary by isotope. For tritium, the exempt quantity is 1,000 µCi (1 mCi); for carbon-14 it is 100 µCi; for iodine-125 it is just 1 µCi. Nanocurie-scale quantities are generally below exempt limits for most isotopes, but universities and companies typically hold broad licenses covering all their work anyway. The license requirements are not about the activity alone — they are about accountability, training, waste disposal, and ensuring that small amounts do not accumulate into large ones through careless stockpiling.

For short-lived isotopes (half-life under 120 days), most institutions use "decay in storage" — the waste sits in a shielded cabinet for 10 half-lives until it is indistinguishable from background, then gets disposed of as normal chemical waste with all radioactive labels removed. For longer-lived isotopes like tritium (12.3-year half-life) or carbon-14 (5,730 years), the waste is collected in designated containers, catalogd by isotope and activity, and shipped to a licensed low-level radioactive waste broker. At nanocurie levels the volumes are small, so the main cost is paperwork, not shielding.

Diagnostic imaging doses fall neatly in the MBq range — a PET scan uses 185–370 MBq, a bone scan 500–800 MBq. Using becquerels would mean writing hundreds of millions; using gigabecquerels would mean awkward decimals like 0.37 GBq. MBq is the Goldilocks unit for the hospital pharmacy: large enough to avoid scientific notation, small enough to express a single patient dose as a tidy number on a syringe label.

That depends entirely on the isotope. Technetium-99m, the workhorse of diagnostic imaging, has a 6-hour half-life — so a 740 MBq injection drops to 370 MBq in 6 hours, 185 MBq in 12, and becomes negligible within 2 days. Fluorine-18 (used in PET) has a 110-minute half-life and is essentially gone in a day. Iodine-131 (used in therapy) lingers for about 8 days per half-life. Hospitals choose isotopes partly based on how fast they want the activity to vanish.

Most diagnostic isotopes (Tc-99m, F-18) have half-lives under a day, so hospitals simply store waste in shielded bins and let it decay. After 10 half-lives — about 3 days for Tc-99m — the activity is down to less than 0.1% of the original and can be disposed of as normal clinical waste. Longer-lived therapeutic isotopes like I-131 require weeks of decay storage. The vast majority of nuclear medicine waste is never shipped to a radioactive disposal site; it just sits in a locked closet until physics solves the problem.

A patient injected with 370 MBq of F-18 for a PET scan emits gamma rays at a dose rate of roughly 5–6 µSv/hr at one meter. That means sitting next to them for two hours gives you about 10–12 µSv — less than a chest X-ray. Staff handle dozens of patients daily so they follow time-and-distance protocols, but for family members the exposure from a single visit is trivially small. The activity halves every 110 minutes, so by evening the patient is barely distinguishable from background.

Molybdenum-99, which decays into the technetium-99m used in 30+ million scans per year worldwide, can only be produced in a handful of aging research reactors. It has a 66-hour half-life so it cannot be stockpiled — you have to make it, ship it, and use it within days. When a reactor goes down for maintenance (as happened in 2009 when both the Canadian NRU and Dutch HFR shut down simultaneously), hospitals worldwide face scan cancellations within a week. New production methods using particle accelerators and LEU targets are slowly diversifying supply.